Safety of secukinumab treatment in COVID ‐19 affected psoriatic patients

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

(2020) Giovanni Damiani et al.   Dermatologic Therapy

COVID ‐19 in an elderly patient treated with secukinumab

(2020) Vito Di Lernia et al.   Dermatologic Therapy

COVID-19 and immunomodulator/immunosuppressant use in dermatology

(2020) Kyla N. Price et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Should biologics for psoriasis be interrupted in the era of COVID-19?

(2020) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy)

(2020) L. Atzori et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy

(2020) Stefano Cafarotti   Journal of Thoracic Oncology

Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury

(2020) Yingxia Liu et al.   National Science Review

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

(2020) Marco Galluzzo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review

(2020) Ilke Coskun Benlidayi et al.   RHEUMATOLOGY INTERNATIONAL